Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Biliary Tract Neoplasms 2Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Malignant Neoplasms of Digestive Organs 1Klatskin Tumor 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Epstein-Barr Virus Infections 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Advanced Biliary Tract Carcinoma 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 5Oxaliplatin 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Fluorouracil 3tivozanib 2Specimen Handling 2Capecitabine 2zimberelimab 1trametinib 1tislelizumab 1quemliclustat 1pertuzumab 1olaparib 1irinotecan sucrosofate 1atezolizumab 1anlotinib 1Yttrium-90 1Tissue Adhesives 1Tegafur 1Stents 1S 1 (combination) 1Ritonavir 1Radiosurgery 1Pancreaticojejunostomy 1Pancreaticoduodenectomy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Tegafur × 1 year × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡